Arcus Biosciences, Inc. (RCUS) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Arcus Biosciences, Inc. (RCUS) Earnings Overview
As of June 20, 2026, Arcus Biosciences, Inc. (RCUS) reported trailing twelve-month net income of -$369M, reflecting -4.8% year-over-year growth. The company earned $-2.94 per diluted share over the past four quarters, with a net profit margin of -142.9%.
Looking at the long-term picture, RCUS's historical earnings data spans multiple years. The company achieved its highest annual net income of $53M in fiscal 2021.
Arcus Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AGEN ($65M net income, 0.1% margin), EXEL ($833M net income, 33.7% margin), HALO ($349M net income, 22.7% margin), RCUS has room to improve margins relative to the peer group. Compare RCUS vs AGEN →
RCUS Earnings vs Peers
Earnings metrics vs comparable public companies
RCUS Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$353M | -24.7% | -$386M | $-3.29 | -142.9% | -156.3% |
| 2024 | -$283M | +7.8% | -$330M | $-3.14 | -109.7% | -127.9% |
| 2023 | -$307M | -15.0% | -$340M | $-4.15 | -262.4% | -290.6% |
| 2022 | -$267M | -603.8% | -$280M | $-3.71 | -238.4% | -250.0% |
| 2021 | $53M | +143.1% | $54M | $0.71 | 13.8% | 14.1% |
| 2020 | -$123M | -45.2% | -$124M | $-2.13 | -157.7% | -159.0% |
| 2019 | -$85M | -70.8% | -$89M | $-1.73 | -564.7% | -591.4% |
| 2018 | -$50M | +6.6% | -$55M | $-1.43 | -593.7% | -656.8% |
| 2017 | -$53M | -195.4% | -$53M | $-2.16 | -3756.7% | -3782.1% |
| 2016 | -$18M | - | -$18M | $-0.73 | - | - |
Download Data
Export RCUS earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RCUS — Frequently Asked Questions
Quick answers to the most common questions about buying RCUS stock.
What is RCUS earnings per share (EPS)?
RCUS trailing twelve-month (TTM) diluted EPS is $-2.94, reflecting -4.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Arcus Biosciences, Inc.'s net income?
Arcus Biosciences, Inc. (RCUS) trailing twelve-month net income is $-369M as of 2025. Earnings declined -4.8% year-over-year.
Is RCUS profitable?
RCUS is not currently profitable on a TTM basis, reporting a net loss of $-369M. Net margin is -142.9%. Investors should monitor for a return to profitability.
What is RCUS's earnings growth rate?
RCUS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are RCUS's profit margins?
Arcus Biosciences, Inc. net profit margin is -142.9%, operating margin is -156.3%, and gross margin is +96.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -63.3%.
Is RCUS growing earnings?
RCUS earnings growth is slowing. Current YoY EPS growth of -4.8% trails the 5-year CAGR of N/A. TTM net income is $-369M.
What was RCUS's best earnings year?
Arcus Biosciences, Inc.'s highest annual net income on record is $53M, achieved in fiscal year 2021. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were RCUS's earnings last quarter?
RCUS's most recent reported quarter was Q1 2026. Net income was $-128M with diluted EPS of $-1.02. For a full breakdown of all quarters, see the quarterly earnings table on this page.